Antibodies mechanisms of action

Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007 39(l-3) 271-8. 

Smith MR. Rituximab (monoclonal anti-CD20 antibody) mechanisms of action and resistance. Oncogene 2003 22 7359-7368. 

Interleukin-1 (IL-1) produced by monocytes and several other cell types [70, 146] has a wide array of biological properties, including T cell activation and inflammatory interactions with muscle, liver, fibroblasts, brain and bone [70, 146], IL-1, both natural and recombinant, has been shown to release histamine from human basophils and from human adenoidal mast cells [70,146,151] and this release was abolished by an IL-1 antibody. However, the average release produced by 10 units of IL-1 was less than 20% and there was considerable variability between populations of basophils in the extent of histamine release. Moreover, the secretory response elicited was quite slow (within 15 min) compared with that of other peptides [151]. Desensitization of the basophils by anti-IgE serum had no effect on the subsequent IL-1 response, suggesting different mechanisms of action [ 151], as has been the case with other peptides. Interestingly, the portion of the IL-1 molecule that is responsible for its immu-nostimulatory activity appears to be separate from that portion responsible for its proinflammatory effects [152]. However, that portion of the molecule responsible for eliciting basophil and mast-cell histamine release has not as yet been defined. 

M. P. Napier, S. K. Sharma, C. J. Springer, K. D. Bagshawe, A. J. Green, J. Martin, S. M. Stribbling, N. Cushen, D. O Malley, R. H. Begent, Antibody-Directed Enzyme Prodrug Therapy Efficacy and Mechanism of Action in Colorectal Carcinoma , Clin. Cancer Res. 2000, 6, 765-772. 

Generate therapeutic antibodies to target Ap for destruction, similar to the example of Herceptin s mechanism of action but it may be difficult to deliver large protein molecules across the blood-brain barrier of the tightly packed endothelial cells. 

Finally, after a brief look at the structure and mechanism of action of enzymes, most of the chapter will be devoted to the innovative and promising field of catalytic antibodies or abzymes, which will probably be the method of choice for preparing optically active compounds in the future. 

Many biopharmaceutical preparations are heterogeneous and may be difficult to fully characterise. Certain fractions of a preparation may have different biological activity or kinetics than the intended product. It is important that such fractions are appropriately qualified. The proportions of these fractions may be altered when production changes are made or they may be different between similar products produced by different manufacturers. Because of their proteinaceous nature and their novel mechanisms of action, all preclinical and clinical development steps must be re-evaluated. For pharmacokinetic studies, blood concentrations should be measured by specific analytical techniques (most often ELISA), which quantify the active protein and not one of its fragments or inactive forms, such as antigen-antibody complexes. For PK-PD studies of monoclonal antibodies, relevant biomarkers are most often circu-... 

Mechanism of Action An immunologic agent that antagonizes purine metabolism and inhibits DNA, protein, and RNA synthesis. Therapeutic Effect Suppresses cell-mediated hypersensitivities alters antibody production and immune response in transplant recipients reduces the severity of arthritis symptoms. 

Mechanism of Action A monoclonal antibody that selectively binds to human immunoglobulin E (IgE) preventing it from binding to the surface of mast cells and basophils. Therapeutic Effect Prevents or reduces the number of asthmatic attacks. Pharmacokinetics Absorbed slowly after subcutaneous administration, with peak concentration in 7-8 days. Excreted in the liver, reticuloendothelial system, and endothelial cells. Half-life 26 days. 

---